Residency · Residency · Cardiothoracic Surgery

Intra-Aortic Balloon Pump and Short-Term MCS Devices

Overview

Short-term mechanical circulatory support (MCS) devices provide temporary hemodynamic support for acute cardiogenic shock or high-risk procedures. These devices range from simple counterpulsation with the IABP to full circulatory support with Impella, TandemHeart, and ECMO. Patient selection, timing of support, and appropriate escalation are critical to outcomes. Temporary MCS serves as a bridge to recovery, decision, durable device, or transplantation.

Intra-Aortic Balloon Pump (IABP)

Mechanism of Action

The IABP works through counterpulsation, using a helium-filled balloon positioned in the descending thoracic aorta and synchronized to the cardiac cycle. Inflation during diastole augments diastolic pressure, improving coronary perfusion and end-organ blood flow. Deflation just before systole reduces aortic end-diastolic pressure (afterload reduction), decreasing myocardial oxygen demand and improving cardiac output. The net hemodynamic effect is a modest increase in cardiac output of 0.3-0.5 L/min, improved coronary flow, and reduced LV work.

Insertion Technique

The IABP is most commonly inserted through percutaneous femoral artery access using a 7.5-8 Fr sheath, though sheathless insertion is also available and carries a lower limb ischemia risk. The balloon tip is positioned 1-2 cm distal to the left subclavian artery, corresponding to the level of the carina on chest X-ray and the aortic knob radiographically. Triggering is synchronized to the ECG or arterial pressure waveform, with 1:1 timing being standard.

Indications

The IABP is used in cardiogenic shock (though the IABP-SHOCK II trial challenged routine use in MI), acute mitral regurgitation or VSD as a bridge to surgery, refractory unstable angina, high-risk PCI support, perioperative support in high-risk cardiac surgery, and failure to wean from CPB as a first-line mechanical support option in many centers.

IABP-SHOCK II Trial

This landmark trial randomized 600 patients with cardiogenic shock complicating acute MI to IABP versus no IABP, with both groups receiving standard medical therapy including PCI. The trial found no significant difference in 30-day mortality (39.7% with IABP versus 41.3% in controls). This result changed clinical practice, leading to the IABP being downgraded from a Class I to a Class IIa/IIb recommendation in guidelines for MI-related cardiogenic shock.

Contraindications

The IABP is contraindicated in severe aortic regurgitation (because diastolic augmentation worsens AR), aortic dissection, severe aortic atherosclerosis or calcification, aortobifemoral grafts, and uncontrolled sepsis or tachyarrhythmia (which prevent appropriate triggering). Severe peripheral arterial disease is a relative contraindication.

Complications

Limb ischemia is the most common complication, occurring in 5-10% of patients, requiring regular monitoring of distal pulses and perfusion. Other complications include vascular injury (dissection, perforation, pseudoaneurysm), thrombocytopenia from mechanical platelet destruction, balloon rupture (manifested by blood in the tubing and loss of augmentation), driveline site infection, and cerebral or visceral embolism (rare).

<image>IABP counterpulsation physiology showing pressure waveforms with diastolic augmentation during balloon inflation and systolic unloading during deflation</image>

Impella Devices

Mechanism

The Impella is an axial flow catheter-mounted pump placed across the aortic valve from the LV to the ascending aorta. It aspirates blood from the LV and ejects it into the ascending aorta, providing continuous forward flow and direct LV unloading.

Device Options

The Impella CP provides up to 4.0 L/min flow through a 14 Fr device with percutaneous femoral access. The Impella 5.0 delivers up to 5.0 L/min but requires surgical cutdown (axillary or femoral artery). The Impella 5.5 provides up to 6.2 L/min via surgical axillary access and allows patient ambulation. The Impella RP provides right-sided support with a percutaneous femoral vein to PA approach, delivering up to 4.0 L/min.

Positioning

Proper position is confirmed by fluoroscopy and echocardiography, with the inlet in the mid-LV cavity and the outlet in the ascending aorta above the aortic valve. The device must avoid entanglement with the mitral valve apparatus. Real-time positioning is monitored through the aortic pressure waveform and motor current signals on the Impella controller.

Indications

The Impella is used for cardiogenic shock (SCAI stages C-E), high-risk PCI hemodynamic support ("protected PCI"), post-cardiotomy shock (failure to wean from CPB), acute MI with cardiogenic shock, and as a bridge to recovery, decision, or durable LVAD/transplant.

Evidence

The DanGer Shock trial (2024) was the first RCT to demonstrate a mortality benefit for Impella CP in acute MI cardiogenic shock. It compared Impella CP plus PCI versus standard of care and showed a significant reduction in 180-day all-cause mortality (45.8% versus 58.5%), establishing Impella CP as an evidence-based therapy in this population. However, higher rates of bleeding and hemolysis were observed in the Impella group.

Complications

Hemolysis is the most common complication, monitored through plasma-free hemoglobin and LDH levels, and may require repositioning or reducing the P-level. Limb ischemia occurs due to the large-bore femoral access (14 Fr), making vascular assessment essential. Device migration or malposition can cause aortic valve damage or reduced support. Vascular access complications include dissection, perforation, and pseudoaneurysm. Bleeding from the access site and anticoagulation, aortic valve injury (rare with proper positioning), and stroke from embolic events are additional risks.

<image>Impella device positioning across the aortic valve with inlet in the left ventricle and outlet in the ascending aorta, demonstrating the principle of direct LV unloading</image>

TandemHeart

Mechanism

The TandemHeart is a percutaneous centrifugal flow pump providing LA-to-femoral artery bypass. A transseptal cannula is placed from the femoral vein through the interatrial septum into the LA, with arterial return via a femoral artery cannula. It provides up to 5.0 L/min flow and directly unloads the LA, reducing LV preload and pulmonary congestion.

Technique

Insertion requires transseptal puncture under fluoroscopic and TEE guidance, with a 21 Fr venous inflow cannula in the LA and a 15-17 Fr arterial outflow cannula in the femoral artery. A centrifugal pump console provides continuous flow.

Advantages and Disadvantages

The TandemHeart provides higher flow support than the IABP, effective LA decompression, and does not cross the aortic valve (useful when aortic valve pathology is present). However, the complex insertion requiring transseptal puncture with echo and fluoroscopy guidance, large-bore access with limb ischemia risk, residual atrial septal defect after decannulation, and inability to use the device in patients with significant right heart failure (which prevents adequate LA filling) limit its use compared to Impella and ECMO.

Device Selection and Escalation

SCAI Cardiogenic Shock Staging

Cardiogenic shock is staged from A through E. Stage A indicates patients at risk with risk factors present but no signs of shock. Stage B represents beginning shock with hypotension and tachycardia but without hypoperfusion. Stage C is classic cardiogenic shock with hypoperfusion manifested by elevated lactate, renal impairment, and altered mentation. Stage D represents deteriorating shock with failure of initial interventions and escalating support requirements. Stage E is extremis with refractory shock, cardiac arrest, or pulseless electrical activity.

Selection Algorithm

For SCAI B-C patients, IABP or Impella CP is appropriate (with the DanGer Shock trial supporting Impella CP in AMI). For SCAI C-D, Impella 5.0/5.5 or VA-ECMO provides the needed level of support. For SCAI D-E, VA-ECMO delivers the highest level of circulatory support. For RV failure, Impella RP, ProtekDuo, or VA-ECMO is used. For biventricular failure, VA-ECMO or bilateral Impella (Impella CP plus Impella RP) is appropriate. The general escalation strategy proceeds from IABP to Impella to ECMO in a stepwise fashion based on hemodynamic response.

Short-Term MCS Device Comparison

SCAI Cardiogenic Shock Staging Summary

LV Unloading with VA-ECMO

VA-ECMO increases LV afterload through retrograde aortic flow, and LV distension can worsen pulmonary edema and prevent myocardial recovery. LV venting strategies include combining Impella with ECMO ("ECPella") for direct LV unloading during ECMO support, adding IABP with ECMO for afterload reduction through counterpulsation, catheter-based atrial septostomy for LA decompression, and surgical LV venting through an apical or LA cannula connected to the ECMO circuit.

<image>SCAI cardiogenic shock staging (A through E) with recommended temporary MCS device escalation pathway for each stage</image>

Weaning and Decannulation

Weaning involves gradual reduction of device support with continuous hemodynamic monitoring. For the IABP, augmentation is decreased from 1:1 to 1:2 to 1:3 with hemodynamic assessment at each step. For Impella, the P-level is gradually reduced while monitoring cardiac output, filling pressures, and vasopressor requirements. Successful weaning is indicated by a cardiac index greater than 2.2 L/min/m2 with minimal or no support, MAP greater than 65 mmHg with low-dose or no vasopressors, mixed venous O2 saturation greater than 60%, normalizing lactate, adequate urine output, and echocardiographic improvement in ventricular function.

Clinical Pearls

The IABP is the simplest temporary MCS device but provides the least hemodynamic support -- it is a starting point, not a definitive therapy for severe cardiogenic shock. IABP-SHOCK II showed no mortality benefit for routine IABP in AMI cardiogenic shock, but the IABP still has utility in other settings such as bridge to surgery and high-risk PCI. DanGer Shock is the first RCT to show a mortality benefit for any percutaneous MCS device (Impella CP) in AMI cardiogenic shock. Hemolysis is the signature complication of Impella, and plasma-free hemoglobin should be monitored daily with device repositioning if hemolysis worsens. LV distension on VA-ECMO is a critical management issue requiring a plan for LV unloading (Impella, IABP, or surgical vent). Early MCS deployment ("door-to-support" time) before profound end-organ damage is associated with better outcomes than rescue deployment in extremis. The right device for the right patient at the right time is the guiding principle -- avoid both under-support (inadequate device) and over-support (unnecessary risk).

References

• Thiele H et al. "Intraaortic balloon support for myocardial infarction with cardiogenic shock (IABP-SHOCK II)." N Engl J Med. 2012.
• Moller JE et al. "Microaxial flow pump or standard care in infarct-related cardiogenic shock (DanGer Shock)." N Engl J Med. 2024.
• Naidu SS et al. "SCAI SHOCK Stage Classification Expert Consensus Update." J Am Coll Cardiol. 2022.
• Ouweneel DM et al. "Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction." J Am Coll Cardiol. 2017.
• Pappalardo F et al. "Concomitant implantation of Impella on top of veno-arterial ECMO (ECPella)." Eur J Heart Fail. 2017.

Read this lecture as Markdown